Literature DB >> 33486140

The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma.

Andrew P Hearn1, Joanne Kavanagh1, Grainne d'Ancona2, Cris Roxas2, Linda Green2, Louise Thomson2, Marianna Fernandes2, Brian D Kent3, Jaideep Dhariwal2, Alexanda M Nanzer2, David J Jackson4.   

Abstract

Entities:  

Year:  2021        PMID： 33486140     DOI： 10.1016/j.jaip.2021.01.008

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  8 in total

Review 1.  Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach.

Authors:  Kazuki Hamada; Keiji Oishi; Yoriyuki Murata; Tsunahiko Hirano; Kazuto Matsunaga
Journal:  J Asthma Allergy       Date:  2021-12-07

2.  IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.

Authors:  Hideyasu Shimizu; Masamichi Hayashi; Hisayuki Kato; Mitsuru Nakagawa; Kazuyoshi Imaizumi; Mitsushi Okazawa
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 3.  A pragmatic guide to choosing biologic therapies in severe asthma.

Authors:  Joanne E Kavanagh; Andrew P Hearn; David J Jackson
Journal:  Breathe (Sheff)       Date:  2021-12

4.  Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE).

Authors:  Marco Contoli; Pierachille Santus; Francesco Menzella; Cindy Rocchi; Dejan Radovanovic; Federico Baraldi; Chiara Martelli; Serena Casanova; Carlo Barbetta; Claudio Micheletto; Nicola Scichilone; Bianca Beghè; Elisiana Carpagnano; Alberto Papi
Journal:  Clin Transl Allergy       Date:  2022-04-07       Impact factor: 5.657

Review 5.  Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.

Authors:  David Charles; Jemma Shanley; Sasha-Nicole Temple; Anna Rattu; Ekaterina Khaleva; Graham Roberts
Journal:  Clin Exp Allergy       Date:  2022-03-09       Impact factor: 5.401

6.  Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.

Authors:  Cristiano Caruso; Paolo Cameli; Elena Altieri; Maria Aliani; Pietro Bracciale; Luisa Brussino; Maria Filomena Caiaffa; Giorgio Walter Canonica; Stefano Centanni; Maria D'Amato; Stefano Del Giacco; Fausto De Michele; Elide Anna Pastorello; Girolamo Pelaia; Paola Rogliani; Micaela Romagnoli; Pietro Schino; Marco Caminati; Alessandra Vultaggio; Alessandro Zullo; Sara Rizzoli; Silvia Boarino; Gianfranco Vitiello; Francesco Menzella; Fabiano Di Marco
Journal:  Front Med (Lausanne)       Date:  2022-09-02

Review 7.  Challenges in severe asthma: Do we need new drugs or new biomarkers?

Authors:  Adil Adatia; Harissios Vliagoftis
Journal:  Front Med (Lausanne)       Date:  2022-09-27

Review 8.  Utilizing Predictive Inflammatory Markers for Guiding the Use of Biologicals in Severe Asthma.

Authors:  Martin Runnstrom; Hilary Pitner; Jennifer Xu; F Eun-Hyung Lee; Merin Kuruvilla
Journal:  J Inflamm Res       Date:  2022-01-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.